Terns Pharma secures exclusive worldwide license for TERN-701 from Hansoh; $1M upfront

Terns Pharmaceuticals, Inc.

Amendment grants Terns exclusive, perpetual, worldwide (excl. Hansoh territory) license to Hansoh patents for TERN-701.
Terns pays $1.0M upfront fee plus tiered royalties of 0.75%-1.25% on net sales covered by licensed patents.
License covers TERN-701 as sole active ingredient; replaces prior non-exclusive, non-sublicensable license.
Hansoh territory remains mainland China, Taiwan, Hong Kong, and Macau.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Terns Pharmaceuticals, Inc. amended Amendment to Exclusive Option and License Agreement with Hansoh (Shanghai) Healthtech Co., Ltd. and certain of its affiliates valued at $1.0 million upfront license fee (effective 2026-01-16).

Action: amendment
Agreement: license
Counterparty: Hansoh (Shanghai) Healthtech Co., Ltd. and certain of its affiliates
Value: $1.0 million upfront license fee
Effective: 2026-01-16

Exact text from the filing

On January 16, 2026, Terns Pharmaceuticals, Inc. (the “Company”) and its subsidiaries entered into an Amendment (the “Amendment”) to its existing Exclusive Option and License Agreement with Hansoh (Shanghai) Healthtech Co., Ltd. and certain of its affiliates (collectively, “Hansoh”), dated July 27, 2020 (the “Option and License Agreement”).

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

Terns Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-019426

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.